NCT07023835 - Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis | Biotech Hunter

Enrollment

240

Participants

Timeline

Start Date

September 17, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

October 31, 2028

Conditions

Amyotrophic Lateral Sclerosis (ALS)

Interventions

DRUG

50 mg Usnoflast

50 mg Usnoflast (50 mg Usnoflast capsules and matching placebo of 25 mg capsule)

DRUG

75 mg Usnoflast

75 mg Usnoflast (25 mg + 50 mg Usnoflast capsules)

DRUG

Placebo

Matching placebo of 25 mg and 50 mg

Trial Locations (15)

15212

NOT_YET_RECRUITING

Zydus 009, Pittsburgh

23298

NOT_YET_RECRUITING

Zydus US004, Richmond

27157

NOT_YET_RECRUITING

Zydus US003, Winston-Salem

30322

NOT_YET_RECRUITING

Zydus US007, Atlanta

48202

NOT_YET_RECRUITING

Zydus US006, Detroit

68510

NOT_YET_RECRUITING

Zydus US014, Lincoln

75206

RECRUITING

Zydus US001, Dallas

77030

NOT_YET_RECRUITING

Zydus US002, Houston

80045

NOT_YET_RECRUITING

Zydus US012, Tampa

92037

NOT_YET_RECRUITING

Zydus US015, La Jolla

92868

NOT_YET_RECRUITING

Zydus US008, Orange

94109

NOT_YET_RECRUITING

Zydus US013, San Francisco

98122

NOT_YET_RECRUITING

Zydus US011, Seattle

06053

NOT_YET_RECRUITING

Zydus US005, New Britain

02114

NOT_YET_RECRUITING

Zydus US010, Boston

All Listed Sponsors

lead

Zydus Therapeutics Inc.

INDUSTRY